Biomarker tests for risk assessment in coronary artery disease: Will they change clinical practice?

Johannes Mair, Allan S. Jaffe

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The clinical significance and economic impact of coronary artery disease has triggered major research efforts into the discovery of novel biomarkers for risk stratification in primary and secondary prevention and then the development of assays suitable for routine measurement. Nevertheless, the clinical impact of these novel biomarkers for risk stratification is still limited because they do not add substantially to traditional risk factors and they only modestly - even with a multimarker approach - improve risk stratification and patient reclassification. The most useful markers appear to be high-sensitivity C-reactive protein, natriuretic peptides, and, eventually, high-sensitivity cardiac troponins. Further research is clearly needed.

Original languageEnglish (US)
Pages (from-to)5-15
Number of pages11
JournalMolecular Diagnosis and Therapy
Volume18
Issue number1
DOIs
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Biomarker tests for risk assessment in coronary artery disease: Will they change clinical practice?'. Together they form a unique fingerprint.

  • Cite this